{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:11:27Z","timestamp":1761059487031},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":6276,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1996,1]]},"abstract":"<jats:p>Mizolastine is a new, nonsedating antihistamine providing satisfactory symptomatic relief in allergic rhinitis and urticaria. The purpose of this study was to use inhibition of wheal and flare formation after 2\u2010\u03bcg intradermal histamine injections as a measure of the antihistamine effect of repeated doses of mizolastine. Eight volunteers were enrolled in this four\u2010arm, double\u2010blind, cross\u2010over, randomized study. Three dose levels of once\u2010daily mizolastine (5 mg, 10 mg, and 15 mg) were compared with placebo during 5\u2010day dose periods. Histamine tests were performed before drug intake on days 1 and 5, and then 2, 3, 4, 6, 8, 10, 12, 14, and 24 hours after drug intake on day 5. All 3 doses of mizolastine were more effective than placebo in suppressing wheal and flare reactions, and the antihistamine activity was highest at both the 10\u2010 and 15\u2010mg dose levels. The effect on the flare reaction appeared within 1 hour, reached a maximum effect 4 hours after administration, and persisted for as long as 24 hours. The relative changes in wheal and flare areas were correlated with mizolastine trough plasma levels on day 5. Safety was satisfactory in all groups. This study confirms that mizolastine is a rapid and potent antihistamine; and its long\u2010lasting effectiveness indicates that a once\u2010daily regimen is acceptable for clinical use.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1996.tb04154.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T18:27:12Z","timestamp":1362767232000},"page":"72-78","source":"Crossref","is-referenced-by-count":12,"title":["Inhibition of Histamine\u2010Induced Skin Wheal and Flare after 5 days of Mizolastine"],"prefix":"10.1002","volume":"36","author":[{"given":"Jean\u2010Louis","family":"Pinquier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri","family":"Caplain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie\u2010Jos\u00e9e","family":"Cabanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Dubruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Stalla\u2010Bourdillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Rosenzweig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)93061-T"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb05638.x"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)93056-V"},{"key":"e_1_2_1_5_2","first-page":"559","article-title":"Antianaphylactic activity of the novel selective histamine H1\u2010receptor antagonist mizolastine in the rodent","volume":"45","author":"L\u00e9vrier J","year":"1995","journal-title":"Arzneim Forsch Drug Res"},{"issue":"16","key":"e_1_2_1_6_2","first-page":"30","article-title":"Mizolastine's effects on psychomotor and actual driving performance in healthy volunteers after single 5, 10, 20 and 40 mg doses vs. clemastine 2 mg and placebo (abstract)","volume":"48","author":"Vuurman P","year":"1993","journal-title":"Eur J Allerg Clin Immunol"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00191164"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)93512-O"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199400920-00006"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(90)90091-H"},{"key":"e_1_2_1_11_2","first-page":"135","article-title":"Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new non sedative H1 antihistamine","volume":"69","author":"Rosenzweig P","year":"1992","journal-title":"Ann Allerg"},{"key":"e_1_2_1_12_2","first-page":"459","article-title":"Comparative wheal and flare study of mizolastine versus terfenadine, cetirizine, loratadine and placebo in healthy volunters","volume":"40","author":"Rosenzweig P","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(80)90198-0"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(93)80117-M"},{"key":"e_1_2_1_15_2","first-page":"169","article-title":"Effect of mizolastine on experimental inflammation in human skin (abstract)","volume":"57","author":"Pinquier JL","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_1_16_2","first-page":"139","article-title":"Compared peripheral H1 inhibiting effect of cetirizine 2 HCL and loratadine","volume":"65","author":"Rihoux JP","year":"1990","journal-title":"Ann Allerg"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00609860"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(89)90377-1"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00637746"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1996.tb04154.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1996.tb04154.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T03:35:43Z","timestamp":1698377743000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1996.tb04154.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1996,1]]}},"alternative-id":["10.1002\/j.1552-4604.1996.tb04154.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1996.tb04154.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,1]]}}}